Navigation Links
Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
Date:4/14/2008

e diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. You are urged to consider statements that include the words "ongoing," "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "suggests," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed in our periodic reports and other filings with the SEC.
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Changes in Management Team
4. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
5. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
6. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
7. TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
8. Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests
11. GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015  Blueprint Medicines ... discover, develop and commercialize novel drug candidates for ... cause of a rare genetic disease. Blueprint Medicines ... identify and optimize drug candidates and will conduct ... an Investigational New Drug (IND) application with the ...
(Date:3/3/2015)... Surgical Company (NASDAQ: STAA ) a leading developer, ... the eye, has named Caren Mason President and ... to STAAR,s Board of Directors in June 2014, and was ... Committee in September 2014, replaces Barry G. Caldwell ... Ms. Mason joins STAAR after most recently serving as CEO ...
(Date:3/3/2015)... 2015 Although lung cancer is the third ... only 18 drugs in the market for its treatment. ... nearing their patent expiry in 2015 and 2017 respectively. ... potential that drug manufacturers are vying to tap into. ... lung cancer (SCLC) and non-small cell lung cancer (NSCLC) ...
Breaking Medicine Technology:Blueprint Medicines Announces Strategic Collaboration with Alexion to Advance Kinase Drug Candidates in Rare Genetic Disease 2Caren Mason Appointed President & CEO of STAAR Surgical Company 2Caren Mason Appointed President & CEO of STAAR Surgical Company 3Caren Mason Appointed President & CEO of STAAR Surgical Company 4Caren Mason Appointed President & CEO of STAAR Surgical Company 5Targeted Lung Cancer Therapies Are Supplanting Conventional Treatments 2Targeted Lung Cancer Therapies Are Supplanting Conventional Treatments 3
... Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR ) today announced ... JMP Securities Tenth Annual Research Conference on ... the Ritz-Carlton in San Francisco. Bank of America Merrill ... at 9:50 a.m. Pacific Time at Encore at Wynn Las ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... extracellular matrix , today announced it plans to ... 6, 2011 before the open of the financial markets. ... with the investment community at 8:00 a.m. PDT (11:00 ...
Cached Medicine Technology:Optimer Pharmaceuticals to Present at May 2011 Investor Conferences 2Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6 2
(Date:3/3/2015)... (PRWEB) March 03, 2015 Using an ... schizophrenia to Medicare Part D prescription drug coverage plans ... annually, a new University of Pittsburgh Graduate School of ... reported in the March issue of the journal Health ... Medicare could have saved more than $5 billion in ...
(Date:3/3/2015)... March 03, 2015 Chicago has long been ... icon, Michael Jordan, brought a level of basketball to Chicago ... to experience again since his Chicago Bulls days in the ... exists to this day. This era also witnessed the birth ... brand. Due to this rich basketball culture, US Sports Camps ...
(Date:3/3/2015)... Nutritional supplement e-tailer PureFormulas has been ... the third ecommerce Conference and Expo, to be ... March 10-12. , PureFormulas CMO Daniel Moure will ... (Melbourne time). His session, entitled “Tapping into People’s ... customer’s experience unique via personalization, as well as ...
(Date:3/3/2015)... United Benefit Advisors (UBA), the nation’s leading ... The Gehring Group, Inc. as its newest Partner Firm. ... 20 years, The Gehring Group is a highly respected, ... firm that serves organizations in the design and implementation ... , Based in Palm Beach Gardens, Florida, and ...
(Date:3/3/2015)... OR (PRWEB) March 03, 2015 A ... severity* confirms what water advocate and radio host Sharon ... dehydration – lack of sufficient water in the body ... much as 90 percent of the US population. Kleyne ... is a factor in nearly all disease, including aging ...
Breaking Medicine News(10 mins):Health News:Medicare and Patients with Schizophrenia Could Save $150 Million on Part D Plans 2Health News:Medicare and Patients with Schizophrenia Could Save $150 Million on Part D Plans 3Health News:US Sports Camps and Nike Basketball Camps Add Five New Locations In and Around Chicago for the Summer of 2015 2Health News:South Florida-based PureFormulas will discuss personalization at ecommerce Conference and Expo in Melbourne, Australia 2Health News:United Benefit Advisors Welcomes New Partner Firm The Gehring Group, Inc. 2Health News:United Benefit Advisors Welcomes New Partner Firm The Gehring Group, Inc. 3Health News:Study linking dehydration and stroke severity supports fresh water advocate’s warnings 2Health News:Study linking dehydration and stroke severity supports fresh water advocate’s warnings 3
... New York University School of Medicine has been honored ... (AAAS) "for his extraordinary leadership to increase the numbers ... workforce.", Dr. Oppenheimwho serves as the Senior ... at New York University School of Medicinewill receive the ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, Feb. 16 ... state-of-the-nation,s health report and the news is mixed, with life ... On the positive side, life expectancy was up slightly ... beginning of the decade. And while women are still ...
... Division of Breast Oncology at the John Theurer Cancer ... Eighth Annual Northern New Jersey Breast Cancer Conference on ... This free continuing medical education (CME) event will ... Cancer Symposium, an international scientific symposium for breast cancer ...
... When doctors discover high concentrations of regulatory T cells in ... grim, though why exactly has long been unclear. ... School of Medicine suggests these regulatory T cells, whose job ... protein that appears to hasten and intensify the spread of ...
... INDIANAPOLIS Researchers from Indiana University-Purdue University Indianapolis (U.S.A) ... in the February 15, 2011, issue of PLoS ... breaks in their DNA, known as Break-induced Replication (BIR), ... genetic mutation than normal cell repair. Accurate transmission ...
... article published in a forthcoming issue of the Journal ... provide evidence of the effectiveness of exposure therapy with ... disorder (PTSD). The study shows that virtual reality exposure ... an average of seven treatment sessions. Additionally, 62 % ...
Cached Medicine News:Health News:2010 AAAS Lifetime Mentor Award goes to Dr. Joel D. Oppenheim of New York University School of Medicine 2Health News:2010 AAAS Lifetime Mentor Award goes to Dr. Joel D. Oppenheim of New York University School of Medicine 3Health News:2010 AAAS Lifetime Mentor Award goes to Dr. Joel D. Oppenheim of New York University School of Medicine 4Health News:America's Health a Mixed Bag: Report 2Health News:America's Health a Mixed Bag: Report 3Health News:John Theurer Cancer Center to host Eighth Annual Northern New Jersey Breast Cancer Conference 2Health News:Key culprit identified in breast cancer metastasis 2Health News:Method of DNA repair linked to higher likelihood of genetic mutation 2Health News:Innovative virtual reality exposure therapy shows promise for returning troops 2
... Patient Isolation Drape features less aggressive ... aggressive adhesive strip for easy removal, ... clear, strong poly film, and product ... in a box of 5 or ...
... bed side and near patient testing is ... growth has posed unique problems for hospitals ... quality responsibility to decentralized areas focused on ... the problem is the reality of controlling ...
... The GenoSensor System includes genomic ... software, and reagents. By utilizing ... (CGH) technology for multi-target assessment, ... analyze multiple genomic targets in ...
... The CELL-DYN 3700 combines optical light ... Polarized Scatter Separation (MAPSS) to fully ... to improve performance and productivity in ... the revolutionary concept of complementary technologies ...
Medicine Products: